AOCI at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's AOCI?
- Summit Therapeutics (SMMT) reported AOCI of -$2.63M in Q1 2026.
- How has Summit Therapeutics's AOCI changed year-over-year?
- Summit Therapeutics's AOCI decreased by 2.7% year-over-year, from -$2.56M to -$2.63M.
- What is the long-term trend for Summit Therapeutics's AOCI?
- Over 5 years (2020 to 2025), Summit Therapeutics's AOCI has grown at a -7.7% compound annual growth rate (CAGR), from -$3.79M to -$2.54M.
- What does AOCI mean?
- The cumulative total of unrealized gains and losses that are excluded from net income.
- How do you interpret AOCI?
- An increase suggests positive impacts from currency translation or investment valuation, while a decrease indicates potential headwinds from foreign exchange or market volatility.
- How does AOCI compare across companies?
- Varies significantly based on the company's international exposure and investment portfolio composition.